SCHEMBL335016

SCHEMBL335016

O=C(Nc1ccccc1OCc1ccccc1)Nc1ccc(Cl)c(S(=O)(=O)N2C[C@@H]3C[C@H]2CN3)c1O

nearest known ligand 0.49

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 18/20 0.49
PPIA P62937 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334435 0.88 CXCR2 (0.64) CXCR2
SCHEMBL333929 0.85 CXCR2 (0.45) CXCR2PPIA
SCHEMBL335944 0.83 CXCR2 (0.60) CXCR2
SCHEMBL10077635 0.83 CXCR2 (0.60) CXCR2
SCHEMBL332558 0.83 CXCR2 (0.45) CXCR2PPIA
SCHEMBL10077636 0.81 CXCR2 (0.64) CXCR2
SCHEMBL334529 0.81 CXCR2 (0.64) CXCR2
SCHEMBL14386143 0.81 CXCR2 (0.46) CXCR2PPIA
SCHEMBL10077656 0.80 CXCR2 (0.64) CXCR2
SCHEMBL334507 0.80 CXCR2 (0.64) CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298810-A1 IL-8 Receptor Antagonists SMITHKLINE BEECHAM CORPORATION 2009-12-03 US claimed
US-8097626-B2 IL-8 receptor antagonists GLAXOSMITHKLINE LLC (US) 2012-01-17 US disclosed
US-8097626-B2 IL-8 receptor antagonists GLAXOSMITHKLINE LLC (US) 2012-01-17 US disclosed
US-20090298810-A1 IL-8 Receptor Antagonists SMITHKLINE BEECHAM CORPORATION 2009-12-03 US disclosed
US-20090298810-A1 IL-8 Receptor Antagonists SMITHKLINE BEECHAM CORPORATION 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298810-A1 IL-8 Receptor Antagonists CXCL8, CCR8, IL1RN CXCR2 6/4885PPIA 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.